Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Other Accumulated Expenses (2017 - 2025)

Aclaris Therapeutics has reported Other Accumulated Expenses over the past 9 years, most recently at $504000.0 for Q4 2025.

  • Quarterly results put Other Accumulated Expenses at $504000.0 for Q4 2025, down 81.22% from a year ago — trailing twelve months through Dec 2025 was $504000.0 (down 81.22% YoY), and the annual figure for FY2025 was $504000.0, down 81.22%.
  • Other Accumulated Expenses for Q4 2025 was $504000.0 at Aclaris Therapeutics, down from $2.7 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for ACRS hit a ceiling of $2.7 million in Q3 2025 and a floor of $173000.0 in Q2 2024.
  • Median Other Accumulated Expenses over the past 5 years was $733000.0 (2022), compared with a mean of $1.4 million.
  • Biggest five-year swings in Other Accumulated Expenses: tumbled 87.49% in 2022 and later skyrocketed 1470.52% in 2025.
  • Aclaris Therapeutics' Other Accumulated Expenses stood at $1.7 million in 2021, then tumbled by 87.49% to $217000.0 in 2022, then surged by 1111.06% to $2.6 million in 2023, then grew by 2.09% to $2.7 million in 2024, then plummeted by 81.22% to $504000.0 in 2025.
  • The last three reported values for Other Accumulated Expenses were $504000.0 (Q4 2025), $2.7 million (Q3 2025), and $2.7 million (Q2 2025) per Business Quant data.